Loren, A W <br/><br/>
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.  [electronic resource] 

 -  Bone marrow transplantation  May 2005 
 - 921-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1704887  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alemtuzumab<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neoplasm--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Female<br/>Graft vs Host Disease--complications<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Lymphoproliferative Disorders--complications<br/>Male<br/>Middle Aged<br/>Mycophenolic Acid--administration & dosage<br/>Transplantation Chimera<br/>Transplantation Conditioning--methods<br/>Vidarabine--administration & dosage